RM
ResMed Inc.
RMD.AX · ASX
$31.95 +1.27% (+$0.40)
1M +0.64%
Market Cap $32.3B
P/E Ratio 21.28x
Div. Yield 0.29%
ROE 23.74%
Bulios Fair Price
$27.21
14.8% downside
Current Price
$31.95
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RMD.AX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
52 /100
Fair P/E 21.28x
PEG 1.86x
EV/EBITDA 14.80x
Growth
89 /100
Growing EPS growth 21.20%
Book val. growth 16.81%
Rev. growth 11.01%
Profitability
100 /100
Strong Gross margin 60.48%
FCF margin 29.16%
Net margin 26.95%
Quality
92 /100
Excellent ROIC 19.19%
Asset turnover 0.63x
ROE 23.74%
Debt
100 /100
Low Debt/Equity 0.13x
Net debt/EBITDA -0.30x
Current ratio 3.10x
Stability
100 /100
Stable Beta 0.74x
Profitable years 6
Rev. volatility 1.21%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RMD.AX
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Michael J. Farrell
Employees
11,370
Headquarters
San Diego
Upcoming events
22 OCT
Earnings
Upcoming earnings report